Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: )

Drug Name
Drug Info
Synonyms
Indication
Disease Entry ICD 11 Status REF
Metastatic colorectal cancer 2B91 Phase 3 [1]
Non-small-cell lung cancer 2C25.Y Phase 3 [1]
Hepatocellular carcinoma 2C12.02 Phase 2 [2]
Hypopharyngeal squamous cell carcinoma 2B6D.0 Phase 1/2 [3]
Cross-matching ID
TTD Drug ID

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [4]
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Inhibitor [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 8.544 6.927 7.253 7.839
Epidermal growth factor receptor (EGFR) DTT EGFR 6.045 4.991 5.317 5.252
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Metastatic colorectal cancer
ICD Disease Classification 2B91
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
2 ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
4 Clinical pipeline report, company report or official report of Roche (2009).